The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
60%, Carnitine, Natural strawberry flavor, Preservative: Potassium sorbate, Zinc gluconate, Acetylcarnitine hydrochloride, Lycopene from tomato (Lycopersicon esculentum Mill., fruit) tit
Thus, while it is a reasonably safe amino acid to supplement with, like everything else, there is a maximum dose
Translating all these advances mentioned above to clinical practice will require the construction of redox phenotyping panels with several biomarkers incorporating various sources of biomolecular and clinical data to guarantee a higher robustness and power of separation for a clinical test (Smith et al., 2021)
:
